Verovaccines Announces EU-Wide Market Authorization for VeroBlue-3 and Strategic Out-Licensing Agreement

Halle (Saale), Germany – April 28, 2026 – Verovaccines GmbH today announced that the European Commission has granted EU-wide market authorization for its VeroBlue-3 bluetongue vaccine, following the positive EMA opinion issued on March 12, 2026. The decision, granted under exceptional circumstances, marks the most significant milestone in the company's history.

VeroBlue-3 is the first product developed on Verovaccines' proprietary platform to receive regulatory approval, establishing the company as a fully integrated vaccine developer and marketing authorization holder (MAH) compliant with EMA standards. The authorization represents a major de-risking event, validating the platform's regulatory pathway, GMP scalability, and suitability as a novel vaccine development engine.

In parallel, Verovaccines has entered into its first out-licensing agreement with an undisclosed top-10 global animal health company, covering manufacturing and EU-wide commercialization. The partnership enables rapid market access while confirming strong industry demand for the platform.

VeroBlue-3 leverages Verovaccines' technology enabling rapid, cost-efficient vaccine development, low cost of goods, thermostability, and flexible combination with existing vaccines - key advantages for addressing fast mutating or emerging pathogens such as bluetongue virus.

Building on this momentum, Verovaccines is actively engaging with multiple pharmaceutical companies in strategic partnering discussions aimed at advancing and broadening its development pipeline. These collaborations focus on leveraging the company's validated platform technology to accelerate the development of new vaccine candidates, including combination products and solutions targeting rapidly evolving pathogens. Through these partnerships, Verovaccines seeks to maximize the value of its platform while enabling partners to access a rapid, de-risked, scalable, and regulatory-proven approach to vaccine development and commercialization.

Dr. Hanjo Hennemann, Managing Director and Co-founder of Verovaccines, said:
"The EU authorization of VeroBlue-3 and our first out-licensing agreement validate both our technology and business model. We are now well positioned to scale, expand our pipeline, and unlock the full value of our platform."

Dr. Ulrike Diesterbeck, DVM, Managing Director of Verovaccines, added:
"The approval of VeroBlue-3 marks a major strategic inflection point, underscoring the platform's scalability and regulatory validation. It establishes a durable foundation for advancing future programs and enabling high-value strategic partnerships."

About Verovaccines

Verovaccines GmbH is a Germany-based biotechnology company developing next-generation vaccines for animal health. Its proprietary platform enables rapid, cost-efficient development of scalable vaccines targeting highly variable pathogens, with advantages including low cost of goods, thermostability, and combination flexibility.

Following its first EU market authorization and validation of GMP manufacturing through a strategic partner, Verovaccines is positioning itself as a high-impact vaccine platform company with strong partnering potential and a scalable development model.

For investor and media inquiries:

Verovaccines GmbH
Bluecherstrasse 26, 06120 Halle (Saale), Germany
Email: info@verovaccines.com
Website: https://verovaccines.com/